Company: CRL
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001100682-25-000021
Chunk: 31

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 2
Chunk 31
---
 of FX(in thousands, except percentages)Revenue$592,609 $605,452 $(12,843)(2.1)%(0.6)%Cost of revenue (excluding amortization of intangible assets)420,143 417,912 2,231 0.5 %Selling, general and administrative65,293 56,859 8,434 14.8 %Amortization of intangible assets13,221 15,842 (2,621)(16.5)%Operating income$93,952 $114,839 $(20,887)(18.2)%2.8 %Operating income % of revenue15.9 %19.0 %(310) bps

DSA revenue decreased $12.8 million primarily due to lower volume driven by continued cautious client spending as a result of the current demand environment and the effect of changes in foreign currency exchange rates.

DSA operating income decreased $20.9 million compared to the corresponding period in 2024. DSA operating income as a percentage of revenue for the three months ended March 29, 2025 was 15.9%, a decrease of 310 bps from 19.0% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to the lower revenue described above, restructuring activities, including asset impairments and site consolidation charges, and certain third-party legal costs incurred in connection with the investigations by the U.S. government into the non-human primate supply chain compared to the corresponding period in 2024.

27 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Manufacturing

Three Months EndedMarch 29, 2025March 30, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$178,486 $185,201 $(6,715)(3.6)%(1.4)%Cost of revenue (excluding amortization of intangible assets)106,997 107,880 (883)(0.8)%Selling, general and administrative34,032 32,847 1,185 3.6 %Amortization of intangible assets46,077 10,793 35,284 326.9 %Operating income (loss)$(8,620)$33,681 $(42,301)(125.6)%(1.2)%Operating income (loss) % of revenue(